针对BCL-XL的BH3模拟剂在具有RB1损失和复制应激反应的固体瘤中具有有效性
Andreas Varkaris1,2, Keshan Wang1,3, Mannan Nouri1
1Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nature communications
|May 28, 2025
概括
在固体瘤中,BH3模仿剂的疗效有限. 然而,缺乏RB1的瘤和受复制压力的瘤对BCL-XL抑制很敏感,这表明了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 针对BCL-2,BCL-XL或MCL-1的BH3模拟剂在固体瘤中表现出有限的有效性.
- 识别特定的瘤弱点和组合策略对于改善癌症治疗结果至关重要.
研究的目的:
- 研究固体瘤对BCL-XL抑制的敏感性,特别是在RB1损失和复制应激的背景下.
- 探索BCL-XL抑制剂敏感性的机制基础.
- 评估结合BCL-XL抑制剂与诱导复制应激的药物的治疗潜力.
主要方法:
- 评估来自异种移植的3D前列腺癌模型和细胞系.
- 药物查以确定使瘤对BCL-XL抑制敏感的药物.
- 涉及TP53/CDKN1A信号和BIRC5表达的机制研究.
- 在活体治疗中使用BCL-2/BCL-XL抑制剂和乳腺腺酸合成酶抑制剂的研究,用于前列腺癌和乳腺癌外移植.
主要成果:
- 患有RB1损失的瘤对BCL-XL抑制具有敏感性.
- 通过胺基酸合成酶抑制剂破坏核酸池,使瘤对BCL-XL抑制产生敏感性,这表明在复制应激下对BCL-XL的依赖性增加.
- 复制应激通过TP53/CDKN1A依赖抑制BIRC5.5.的抑制使细胞对BCL-XL抑制敏感.
- 与纳维托克拉克斯和胺酸合成酶抑制剂 (拉尔提特雷克斯或卡佩奇他) 的联合治疗导致异种移植模型中的显著和持久的瘤回归.
结论:
- BCL-XL 抑制剂在具有 RB1 损失的固体瘤中作为单一疗法可能是有效的.
- 复制应激的药理诱导是一种有前途的策略,可以使更广泛的固体瘤对BCL-XL抑制剂产生敏感性.
- 这些发现支持开发用于前列腺癌和乳腺癌的新型组合疗法.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The Retinoblastoma Gene
4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
The Intrinsic Apoptotic Pathway
9.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K


